• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Induction chemotherapy with paclitaxel, cisplatin and capecitabine showed promising clinical and safety response to treat advanced nasopharyngeal carcinoma

byJamie ParkandSze Wah Samuel Chan
April 4, 2022
in ENT, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The failure-free-survival at 3 years for induction chemotherapy with paclitaxel, cisplatin and capecitabine group was 83.5% versus 68.9% in the cisplatin and fluorouracil group.

2. Common treatment-related adverse events in patients receiving paclitaxel, cisplatin and capecitabine were nephrotoxicity, hand-foot syndrome and allergic reaction.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The current standard of care for non-metastatic nasopharyngeal carcinoma (NPC) is induction chemotherapy with concurrent chemoradiotherapy. However, there is limited knowledge on the optimal induction regimen for NPC. Therefore, this study aimed to compare the efficacy and safety of induction chemotherapy with paclitaxel, cisplatin and capecitabine (TPC) versus cisplatin and fluorouracil (PF) for patients with stage IVA to IVB NPC. In the intention-to-treat group, the failure-free-survival at 3 years for TPC group was 83.5% versus 68.9% in the PF group. Nephrotoxicity, hand-foot syndrome and allergic reaction were common treatment-related adverse events that were reported. The main limitation of the analyses included limited data for diverse ethnicities as the study was conducted in Chinese patients only. Overall, this study demonstrated support that TPC can be used as induction chemotherapy for stage IVA to IVB NPC. However, further investigation is required to examine the long-term survival and safety profile of this induction chemotherapy regimen.

Click to read the study in JAMA Oncology

Relevant Reading: Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomized controlled trial.

In-Depth [randomized controlled trial]: This was an open label, randomized, multi-center phase III study. A total of 238 patients were enrolled to receive either study treatment (n=118) or cisplatin and fluorouracil (n=120) induction chemotherapy. In addition, all patients received concurrent chemoradiotherapy with cisplatin. The demographic of both study groups were well-balanced. The median follow-up period was 48.4 months (interquartile range [IQR]: 39.6-53.3). The failure-free-survival at 3 years for the intention-to-treat population was 83.5% (95% confidence interval [CI]: 77.0%-90.6%) in the TPC group and 68.9% in the PF group (95% CI: 61.1%-77.8%). The stratified hazard ratio [HR] was 0.47 [95% CI: 0.28-0.79; p=0.004]. Common treatment-related adverse events of any grade for included nephrotoxicity (TPC: 94.9%, PF: 93.3%), hand-foot syndrome (TPC: 98.3%, PF: 99.2%) and allergic reaction (TPC: 94.9%, PF: 97.5%). 57.6% of the patients in the TPC group versus 13.6% in the PF group experienced grade 3-4 acute adverse events and late-onset toxicities. There was one treatment-related death in the PF group.

RELATED REPORTS

Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma

#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: induction chemotherapynasopharyngeal carcinomaTPC chemotherapy
Previous Post

Barriers to medication access for opioid use disorder in adolescents and young adults

Next Post

Steep decline in post-operative opioid prescriptions for common pediatric surgeries

RelatedReports

No difference in PET-CT surveillance versus planned neck dissection in advanced head and neck cancer
Chronic Disease

Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma

March 29, 2023
#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma
StudyGraphics

#StudyGraphics: Concomitant chemoradiotherapy improves survival in elderly adults with locally advanced head and neck squamous cell carcinoma

March 9, 2023
#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Adjuvant capecitabine improves clinical outcomes in patients with locally advanced nasopharyngeal carcinoma

January 25, 2023
#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma
StudyGraphics

#VisualAbstract: Intensity-modulated radiotherapy alone is noninferior to concurrent chemoradiotherapy for low-risk nasopharyngeal carcinoma

October 25, 2022
Next Post

Steep decline in post-operative opioid prescriptions for common pediatric surgeries

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

#VisualAbstract: Neoadjuvant HD201 shows similar efficacy to referent trastuzumab for ERBB2-positive breast cancer

Repeat bone mineral density testing may not improve prediction of fracture outcomes

Bone mineral density testing beneficial for older men receiving androgen deprivation therapy for localized or regional prostate cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Exhaled volatile organic compounds predict bronchopulmonary dysplasia in preterm infants
  • Wellness Check: Mental Health
  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options